Lipitor's

The event is a turning point not only for Lipitor's maker, Pfizer, but also for the entire pharmaceutical industry.

Big Pharma's New Business Model Scott Gottlieb 2011

But Zocor went off patent in 2006, and Lipitor's patent expires later this year, opening the market to competition from cheaper generics.

Abbott Dealt Blow in Cholesterol Drug Trial Ron Winslow 2011

Branded Lipitor's share has come down in recent weeks, though some analysts say it is still higher than what other big-selling drugs have achieved historically at similar points following loss of exclusivity.

WellPoint to Cease Branded Lipitor Coverage, Favor Generics Jon Kamp 2012

The legal analysis raises the question whether Lipitor's advertisements, which omit that Lipitor's clinical trial found slight increased risk for women, is consistent with the Food, Drug, and Cosmetics Act and related Food and Drug Administration (FDA) regulations.

Archive 2009-04-01 Rebecca Tushnet 2009

"Right, schmight," the voice replied, "this is 2012 and if you eat that pie, you're gonna be all over YouTube and Facebook, and Lipitor's sales reps are gonna be camping on your doorstep."

Al Eisele: The Death of Privacy Al Eisele 2012

Billions of dollars in sales of AstraZeneca's Crestor could be at risk from Lipitor's transition to a cheap generic drug.

Astra Slides as Drug Fails to Top Rival Sten Stovall 2011

J.P. Morgan released a report Monday saying new generic version of Lipitor captured about 14.6% of U.S. prescription volume for drugs containing Lipitor's active ingredient in the first few days after their launch.

Pfizer Lifts Payout, Buyback Peter Loftus 2011

None will come close to matching Lipitor's $10.7 billion in 2010 revenue, so Pfizer's top line will continue to shrink.

Leaner Pfizer Expects Clean Bill of Health Spencer Jakab 2012

Investors have closely watched Pfizer's financial targets for 2012 because it will be the first full year after Lipitor's U.S. patent expiration in November.

Pfizer to Cut Research, Shift Funding to Buybacks Peter Loftus 2011

The effort, if successful, could help Pfizer squeeze new sales life out of the world's best-selling drug in the years after Lipitor loses U.S. patent protection in November, which will trigger sales-eroding generic competition that will eat into Lipitor's current yearly haul of nearly $11 billion.

Pfizer Looks At Lipitor Over Counter Peter Loftus 2011